161 related articles for article (PubMed ID: 25808864)
41. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
42. Reactivation of low avidity tumor-specific CD8
Sugiyarto G; Lau D; Hill SL; Arcia-Anaya D; Boulanger DSM; Parkes E; James E; Elliott T
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586767
[TBL] [Abstract][Full Text] [Related]
43. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
[TBL] [Abstract][Full Text] [Related]
44. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
45. Unpredicted phenotypes of two mutants of the TcR DMF5.
Tadesse FG; Mensali N; Fallang LE; Walseng E; Yang W; Olweus J; Wälchli S
J Immunol Methods; 2015 Oct; 425():37-44. PubMed ID: 26079729
[TBL] [Abstract][Full Text] [Related]
46. Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.
Soler M; Li X; John-Herpin A; Schmidt J; Coukos G; Altug H
ACS Sens; 2018 Nov; 3(11):2286-2295. PubMed ID: 30339020
[TBL] [Abstract][Full Text] [Related]
47. Evidence that the density of self peptide-MHC ligands regulates T-cell receptor signaling.
Anikeeva N; Gakamsky D; Schøller J; Sykulev Y
PLoS One; 2012; 7(8):e41466. PubMed ID: 22870225
[TBL] [Abstract][Full Text] [Related]
48. CD3 downregulation identifies high-avidity human CD8 T cells.
Clutton GT; Weideman AMK; Mischell MA; Kallon S; Conrad SZ; Shaw FR; Warren JA; Lin L; Kuruc JD; Xu Y; Gay CM; Armistead PM; G Hudgens M; Goonetilleke NP
Clin Exp Immunol; 2024 Feb; 215(3):279-290. PubMed ID: 37950348
[TBL] [Abstract][Full Text] [Related]
49. Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Schmidt J; Guillaume P; Irving M; Baumgaertner P; Speiser D; Luescher IF
J Biol Chem; 2011 Dec; 286(48):41723-41735. PubMed ID: 21990358
[TBL] [Abstract][Full Text] [Related]
50. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.
Campillo-Davo D; Flumens D; Lion E
Cells; 2020 Jul; 9(7):. PubMed ID: 32708366
[TBL] [Abstract][Full Text] [Related]
51. Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.
Gilfillan CB; Hebeisen M; Rufer N; Speiser DE
Eur J Immunol; 2021 Jun; 51(6):1348-1360. PubMed ID: 33704770
[TBL] [Abstract][Full Text] [Related]
52. High-Throughput Single-Cell TCR-pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit.
Jammes F; Schmidt J; Coukos G; Maerkl SJ
ACS Sens; 2022 Jan; 7(1):159-165. PubMed ID: 35006683
[TBL] [Abstract][Full Text] [Related]
53. Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.
Blanchfield JL; Shorter SK; Evavold BD
Front Immunol; 2013; 4():170. PubMed ID: 23840195
[TBL] [Abstract][Full Text] [Related]
54. Relationship of 2D Affinity to T Cell Functional Outcomes.
Kolawole EM; Lamb TJ; Evavold BD
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33120989
[TBL] [Abstract][Full Text] [Related]
55. Nanoscale organization of two-dimensional multimeric pMHC reagents with DNA origami for CD8
Sun Y; Yan L; Sun J; Xiao M; Lai W; Song G; Li L; Fan C; Pei H
Nat Commun; 2022 Jul; 13(1):3916. PubMed ID: 35798752
[TBL] [Abstract][Full Text] [Related]
56. The quantum chemical causality of pMHC-TCR biological avidity: Peptide atomic coordination data and the electronic state of agonist N termini.
Antipas GS; Germenis AE
Data Brief; 2015 Jun; 3():180-4. PubMed ID: 26217741
[TBL] [Abstract][Full Text] [Related]
57. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.
Alexander-Miller MA
Immunol Res; 2005; 31(1):13-24. PubMed ID: 15591619
[TBL] [Abstract][Full Text] [Related]
58. Insights into T cell recognition of antigen: significance of two-dimensional kinetic parameters.
Edwards LJ; Zarnitsyna VI; Hood JD; Evavold BD; Zhu C
Front Immunol; 2012; 3():86. PubMed ID: 22566966
[TBL] [Abstract][Full Text] [Related]
59. Microfluidic T Cell Selection by Cellular Avidity.
Ashby JF; Schmidt J; Kc N; Kurum A; Koch C; Harari A; Tang L; Au SH
Adv Healthc Mater; 2022 Aug; 11(16):e2200169. PubMed ID: 35657072
[TBL] [Abstract][Full Text] [Related]
60. Global k
Lückemeier P; Molter KL; Jarosch S; Huppertz P; Purcarea A; Effenberger MJP; Nauerth M; D'Ippolito E; Schober K; Busch DH
Eur J Immunol; 2022 Apr; 52(4):582-596. PubMed ID: 35099805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
